Global Health Ltd (Medanta) Reports Strong Q1 FY27 Growth

Consolidated Income: ₹1,326.2 crore
Profit After Tax (PAT): ₹157.3 crore

Reader Takeaway: Volume-driven growth and Noida facility ramp-up drive performance, offset by prior-year exceptional gain.

What just happened

Global Health Limited, operating under the Medanta brand, announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27). The company reported a consolidated income of ₹1,326.2 crore, marking a significant 26% increase compared to the same period last year. Reported EBITDA stood at ₹315.3 crore, with EBITDA excluding the Noida facility at ₹320.1 crore. Profit After Tax (PAT) for the quarter was ₹157.3 crore.

Why this matters

The strong income growth, driven by operational volumes, indicates sustained demand for Medanta's services. The improved performance of the Noida facility, with its EBITDA loss narrowing substantially, is a key positive. This suggests that the company's expansion strategies and operational leverage are beginning to yield results, potentially leading to better profitability.

The backstory

In Q1 FY26, Global Health had reported a PAT of ₹159.0 crore. However, the current quarter's PAT of ₹157.3 crore is slightly lower due to a prior-year exceptional gain of ₹19.6 crore related to the reversal of a potential interest liability. The company's operational bed capacity has reached 3,737 beds, with recent additions in Noida and Lucknow.

What changes now

With the Noida facility showing a significant turnaround, its contribution to the company's overall profitability is expected to improve. The focus will now be on reaching full utilization and operational maturity at Noida, alongside the continued expansion of capacity, such as the revised Guwahati hospital project. The company's strategy hinges on volume growth and operational efficiency rather than significant tariff increases.

Risks to watch

While the Noida facility's losses are decreasing, it is still in a ramp-up phase. Its future margin performance is contingent on achieving faster utilization. Additionally, certain specialty service mixes might experience seasonal fluctuations, impacting quarterly performance. Investors are advised to consider annualized results for a clearer picture.

Peer comparison

While specific peer data for this quarter is not provided in the filing, Global Health's performance is set against a backdrop of increasing demand for quality healthcare services in Central and Northern India. The company's expansion into new geographies like Guwahati and the focus on operational leverage at its newer facilities are key differentiators.

Context metrics (time-bound)

• In Q1 FY27, inpatient volumes grew 28% and outpatient volumes increased by 34% across the network.
• The Noida facility's income rose to ₹85.5 crore in Q1 FY27 from ₹52.5 crore in Q4 FY26.
• The Noida facility's EBITDA loss narrowed to ₹4.9 crore from ₹23.6 crore in the previous quarter.
• Operational bed capacity stands at 3,737 beds, with 72 added in the current quarter.

What to track next

Investors should closely monitor the utilization rates and profitability of the Noida facility. The progress and cost management of the new Guwahati hospital project, planned as a 650-bed super specialty facility with an estimated cost of ₹970 crore, will also be crucial indicators for future growth.